RCRC
20.1.2020 12:45:11 CET | Business Wire | Press release
Saudi Arabia’s King Salman Bin Abdul Aziz Al Saud has appointed Fahd Abdulmohsan Al-Rasheed as President of the Royal Commission for Riyadh City (RCRC), following his appointment in 2018 as Advisor at the Royal Court.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200120005223/en/
Al-Rasheed’s career has featured various leadership roles in key Saudi public and private sector organizations. From January 2008 to September 2018, he served as Chief Executive Officer and Board member of Emaar the Economic City, the publicly listed developer of the King Abdullah Economic City (KAEC).
KAEC is not only the first publicly listed greenfield city in the world, but is also considered one of the largest private sector led projects globally. Located on the Red Sea coast of Saudi Arabia and covering 181 square kilometers, it contains advanced urban and environmental sustainability features. During his tenure at KAEC, Al-Rasheed spearheaded the development of King Abdullah Port, the first private port in the region and one of the world’s 100 largest port facilities. Over 120 local and international companies established a corporate or industrial base in KAEC, making it a leading regional center for logistic and industrial services. Concurrently, Al-Rasheed led the development of multiple residential, utility and recreational projects to make the Economic City an attractive, integrated tourism and residential destination.
Previously, Al-Rasheed served as CFO & Deputy Governor at the Saudi Arabian General Investment Authority (SAGIA) and worked at Saudi Aramco, where he led several corporate finance initiatives.
In addition to his new position as RCRC President, Fahd Al-Rasheed will continue his roles as:
- Vice Chairman of the Board of Trustees of the Prince Mohammed bin Salman College of Business and Entrepreneurship – the first of its kind in the Kingdom – which aims to be an incubator and trainer of business entrepreneurs and future leaders across key sectors (governmental, private sector and civil community foundations). MiSK Foundation, Babson International College and Lockheed Martin Corporation are amongst the college’s founders;
- Founder and Chairman of the non-profit Red Sea Foundation, based in Geneva, which promotes trade across the Red Sea region;
- Board Member of the New Cities Foundation (a non-profit foundation based in Geneva);
- Board Member of Emaar Economic City; King Abdullah Port; and the Diplomatic Quarters Authority in Riyadh.
Al-Rasheed was honored as a Young Global Leader by the World Economic Forum in 2011.
He holds a bachelor’s degree in Business Administration from Washington University in St. Louis, USA, and an MBA from Stanford Business School. He graduated from the Advanced Management Program in Real Estate Development at the Harvard Graduate School of Design.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
